Trifluoperazine, an antipsychotic agent, inhibits cancer stem cell growth and overcomes drug resistance of lung cancer

American Journal of Respiratory and Critical Care Medicine

Volumn 186, Issue 11, 2012, Pages 1180-1188

  Yeh, Chi Tai ^a,b,c   Wu, Alexander T H ^a,d   Chang, Peter M H ^e,f   Chen, Kuan Yu ^g   Yang, Chia Ning ^h   Yang, Shuenn Chen ⁱ   Ho, Chao Chi ^g   Chen, Chun Chi ^i,n   Kuo, Yu Lun ^k   Lee, Pei Ying ^f   Liu, Yu Wen ^f   Yen, Chueh Chuan ^e,f   Hsiao, Michael ^j   Lu, Pei Jung ^l   Lai, Jin Mei ^m   Wang, Liang Shun ^a,b   Wu, Chih Hsiung ^b   Chiou, Jeng Fong ^d   Yang, Pan Chyr ^g,i,k   Huang, Chi Ying F ^f  

^a TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^c NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

^d TAIPEI MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^e TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^f NATIONAL YANG MING UNIVERSITY   (Taiwan)

^g NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^h NATIONAL UNIVERSITY OF KAOHSIUNG   (Taiwan)

ⁱ INSTITUTE OF BIOMEDICAL SCIENCES   (Taiwan)

^j GENOMICS RESEARCH CENTER   (Taiwan)

^k NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^l NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^m FU JEN CATHOLIC UNIVERSITY   (Taiwan)

ⁿ INSTITUTE OF MICROBIOLOGY   (China)

more..

Author keywords

Cancer stem cell; Connectivity map; Gefitinib; Lung cancer; Trifluoperazine

Indexed keywords

ACEPROMAZINE; BETA CATENIN; CHLORPROMAZINE; CISPLATIN; ERLOTINIB; FLUPHENAZINE; GEFITINIB; PERPHENAZINE; PHENOTHIAZINE; PROCHLORPERAZINE; PROMAZINE; PROTEIN TYROSINE KINASE INHIBITOR; TRIFLUOPERAZINE; TRIFLUPROMAZINE; WNT PROTEIN;

ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER STEM CELL; COMPUTER MODEL; DOWN REGULATION; DRUG POTENTIATION; DRUG SCREENING; DRUG STRUCTURE; EMBRYONIC STEM CELL; FEMALE; GENE EXPRESSION PROFILING; LUNG CANCER; MALE; METASTASIS; MOUSE; MULTIPLE CYCLE TREATMENT; NONHUMAN; PRIORITY JOURNAL; SCORING SYSTEM;

ANIMALS; ANTIPSYCHOTIC AGENTS; APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, NEOPLASM; LUNG NEOPLASMS; MICE; MICE, INBRED NOD; MICE, SCID; NEOPLASTIC STEM CELLS; QUINAZOLINES; RANDOM ALLOCATION; SENSITIVITY AND SPECIFICITY; TRIFLUOPERAZINE; TUMOR CELLS, CULTURED;

EID: 84870421832     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201207-1180OC     Document Type: Article

References (44)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62:10-29.
2. Pfister DG, Johnson DH, Azzoli CG, Sause W, Smith TJ, Baker S Jr, Olak J, Stover D, Strawn JR, Turrisi AT, et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: Update 2003. J Clin Oncol 2004;22:330-353. (Pubitemid 41095099)
3. Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, Dewhirst MW, Bigner DD, Rich JN. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006;444:756-760. (Pubitemid 44949604)
4. Diehn M, Cho RW, Lobo NA, Kalisky T, Dorie MJ, Kulp AN, Qian D, Lam JS, Ailles LE, Wong M, et al. Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature 2009;458:780-783.
5. Gupta PB, Onder TT, Jiang G, Tao K, Kuperwasser C, Weinberg RA, Lander ES. Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell 2009;138:645-659.
6. Clevers H. The cancer stem cell: premises, promises and challenges. Nat Med 2011;17:313-319.
7. Eramo A, Lotti F, Sette G, Pilozzi E, Biffoni M, Di Virgilio A, Conticello C, Ruco L, Peschle C, De Maria R. Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ 2008;15:504-514. (Pubitemid 351267301)
8. Pirozzi G, Tirino V, Camerlingo R, Franco R, La Rocca A, Liguori E, Martucci N, Paino F, Normanno N, Rocco G. Epithelial to mesenchymal transition by TGF beta-1 induction increases stemness characteristics in primary non small cell lung cancer cell line. PLoS ONE 2011;6:e21548.
9. Leung EL, Fiscus RR, Tung JW, Tin VP, Cheng LC, Sihoe AD, Fink LM, Ma Y, Wong MP. Non-small cell lung cancer cells expressing CD44 are enriched for stem cell-like properties. PLoS ONE 2010;5:e14062.
10. Storms RW, Goodell MA, Fisher A, Mulligan RC, Smith C. Hoechst dye efflux reveals a novel CD7(+)CD34(-) lymphoid progenitor in human umbilical cord blood. Blood 2000;96:2125-2133.
11. Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M, Jacquemier J, Viens P, Kleer CG, Liu S, et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 2007;1:555-567. (Pubitemid 350056407)
12. Ozvegy-Laczka C, Hegedus T, Varady G, Ujhelly O, Schuetz JD, Varadi A, Keri G, Orfi L, Nemet K, Sarkadi B. High-affinity interaction of tyrosine kinase inhibitors with the ABCG2 multidrug transporter. Mol Pharmacol 2004;65:1485-1495. (Pubitemid 38668306)
13. Shats I, Gatza ML, Chang JT, Mori S, Wang J, Rich J, Nevins JR. Using a stem cell-based signature to guide therapeutic selection in cancer. Cancer Res 2011;71:1772-1780.
14. Wong DJ, Liu H, Ridky TW, Cassarino D, Segal E, Chang HY. Module map of stem cell genes guides creation of epithelial cancer stem cells. Cell Stem Cell 2008;2:333-344. (Pubitemid 351455242)
15. Kim J,Woo AJ, Chu J, Snow JW, Fujiwara Y, Kim CG, Cantor AB, Orkin SH. A Myc network accounts for similarities between embryonic stem and cancer cell transcription programs. Cell 2010;143:313-324.
16. Lamb J, Crawford ED, Peck D, Modell JW, Blat IC, Wrobel MJ, Lerner J, Brunet JP, Subramanian A, Ross KN, et al. The connectivity map: using gene-expression signatures to connect small molecules, genes, and disease. Science 2006;313:1929-1935. (Pubitemid 44497995)
17. Zufferey R, Nagy D, Mandel RJ, Naldini L, Trono D. Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo. Nat Biotechnol 1997;15:871-875.
18. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984;22:27-55.
19. Engelman JA, Zejnullahu K, Gale CM, Lifshits E, Gonzales AJ, Shimamura T, Zhao F, Vincent PW, Naumov GN, Bradner JE, et al. Pf00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib. Cancer Res 2007;67:11924-11932.
20. Yan Y, Lu Y, Wang M, Vikis H, Yao R, Wang Y, Lubet RA, You M. Effect of an epidermal growth factor receptor inhibitor in mouse models of lung cancer. Mol Cancer Res 2006;4:971-981. (Pubitemid 46121555)
21. Liu H, Patel MR, Prescher JA, Patsialou A, Qian D, Lin J, Wen S, Chang YF, Bachmann MH, Shimono Y, et al. Cancer stem cells from human breast tumors are involved in spontaneous metastases in orthotopic mouse models. Proc Natl Acad Sci USA 2010;107:18115-18120.
22. Zhang M, Rosen JM. Stem cells in the etiology and treatment of cancer. Curr Opin Genet Dev 2006;16:60-64. (Pubitemid 43089613)
23. Ben-Porath I, Thomson MW, Carey VJ, Ge R, Bell GW, Regev A, Weinberg RA. An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat Genet 2008;40:499-507. (Pubitemid 351601215)
24. Somervaille TC, Matheny CJ, Spencer GJ, Iwasaki M, Rinn JL, Witten DM, Chang HY, Shurtleff SA, Downing JR, Cleary ML. Hierarchical maintenance of MLL myeloid leukemia stem cells employs a transcriptional program shared with embryonic rather than adult stem cells. Cell Stem Cell 2009;4:129-140.
25. Ramalho-Santos M, Yoon S, Matsuzaki Y, Mulligan RC, Melton DA. Stemness: transcriptional profiling of embryonic and adult stem cells. Science 2002;298:597-600. (Pubitemid 35215313)
26. Suva ML, Riggi N, Janiszewska M, Radovanovic I, Provero P, Stehle JC, Baumer K, Le Bitoux MA, Marino D, Cironi L, et al. EZH2 is essential for glioblastoma cancer stem cell maintenance. Cancer Res 2009;69:9211-9218.
27. Sachlos E, Risueno RM, Laronde S, Shapovalova Z, Lee JH, Russell J, Malig M, McNicol JD, Fiebig-Comyn A, Graham M, et al. Identification of drugs including a dopamine receptor antagonist that selectively target cancer stem cells. Cell 2012;149:1284-1297.
28. Paul S, Dey A. Wnt signaling and cancer development: therapeutic implication. Neoplasma 2008;55:165-176.
29. Nguyen DX, Chiang AC, Zhang XH, Kim JY, Kris MG, Ladanyi M, Gerald WL, Massague J. WNT/TCF signaling through LEF1 and HOXB9 mediates lung adenocarcinoma metastasis. Cell 2009;138:51-62.
30. Mazieres J, He B, You L, Xu Z, Jablons DM. Wnt signaling in lung cancer. Cancer Lett 2005;222:1-10. (Pubitemid 40544841)
31. Seeman P, Lee T, Chau-Wong M, Wong K. Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature 1976;261:717-719.
32. Marques LO, Lima MS, Soares BG. Trifluoperazine for schizophrenia. Cochrane Database Syst Rev 2004;CD003545.
33. Vandonselaar M, Hickie RA, Quail JW, Delbaere LT. Trifluoperazine-induced conformational change in Ca(21)-calmodulin. Nat Struct Biol 1994;1:795-801.
34. Pan D, Yan Q, Chen Y, McDonald JM, Song Y. Trifluoperazine regulation of calmodulin binding to Fas: a computational study. Proteins 2011;79:2543-2556.
35. Chen QY, Wu LJ, Wu YQ, Lu GH, Jiang ZY, Zhan JW, Jie Y, Zhou JY. Molecular mechanism of trifluoperazine induces apoptosis in human A549 lung adenocarcinoma cell lines. Mol Med Report 2009;2:811-817.
36. Shin SY, Choi BH, Kim JR, Kim JH, Lee YH. Suppression of P-glycoprotein expression by antipsychotics trifluoperazine in adriamycin-resistant l1210 mouse leukemia cells. Eur J Pharm Sci 2006;28:300-306. (Pubitemid 43776199)
37. Shin SY, Kim CG, Hong DD, Kim JH, Lee YH. Implication of Egr-1 in trifluoperazine-induced growth inhibition in human U87MG glioma cells. Exp Mol Med 2004;36:380-386. (Pubitemid 39279535)
38. Hendrich AB, Wesolowska O, Michalak K. Trifluoperazine induces domain formation in zwitterionic phosphatidylcholine but not in charged phosphatidylglycerol bilayers. Biochim Biophys Acta 2001;1510:414-425. (Pubitemid 32149914)
39. Ford JM, Prozialeck WC, Hait WN. Structural features determining activity of phenothiazines and related drugs for inhibition of cell growth and reversal of multidrug resistance. Mol Pharmacol 1989;35:105-115. (Pubitemid 19048639)
40. Ganapathi R, Kuo T, Teeter L, Grabowski D, Ford J. Relationship between expression of P-glycoprotein and efficacy of trifluoperazine in multidrug-resistant cells. Mol Pharmacol 1991;39:1-8.
41. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646-674.
42. Casas-Selves M, Kim J, Zhang Z, Helfrich BA, Gao D, Porter CC, Scarborough HA, Bunn PA Jr, Chan DC, Tan AC, et al. Tankyrase and the canonical Wnt pathway protect lung cancer cells from EGFR inhibition. Cancer Res 2012;72:4154-4164.
43. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J, Johnson DH. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346:92-98. (Pubitemid 34438899)
44. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947-957.